Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares of Stock

Key Points

• Insider sale: Andrew Stewart Plump sold 165,393 Takeda shares at an average price of $17.10, worth approximately $2.83 million. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 17.75%.
• Stock performance: Takeda shares recently traded at $17.42, with a 52-week range of $12.99 to $18.90 and a market capitalization of about $55.82 billion.
• Analyst outlook: Analyst opinions are mixed—two rate the stock Buy, one Hold and one Sell—resulting in a consensus “Hold” rating. Institutional investors own approximately 9.17% of the company.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Andrew Stewart Plump sold 165,393 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30. Following the transaction, the insider owned 766,569 shares in the company, valued at $13,108,329.90. This trade represents a 17.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

TAK stock traded down $0.06 during trading on Wednesday, hitting $17.42. 2,004,364 shares of the company's stock traded hands, compared to its average volume of 4,402,927. The stock has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The stock has a fifty day moving average price of $16.49 and a two-hundred day moving average price of $17.13. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $6.90 billion during the quarter. As a group, equities analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of TAK. Capital Research Global Investors raised its position in Takeda Pharmaceutical by 0.6% in the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company's stock worth $210,259,000 after acquiring an additional 82,643 shares in the last quarter. UBS Group AG boosted its position in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company's stock valued at $86,288,000 after purchasing an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company's stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company's stock valued at $55,358,000 after purchasing an additional 370,800 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

TAK has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings cut Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source